Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
5
×
rna interference
5
×
alnylam pharmaceuticals
biotech
boston top stories
clinical trials
national top stories
boston
deals
new york blog main
alexion pharmaceuticals
alirocumab
amgen
boehringer ingelheim
evolocumab
fda
hepatitis b
inclisiran
new york
new york top stories
pcsk9 inhibitors
regeneron pharmaceuticals
san francisco blog main
sanofi
alnylam pharmaceutials
amy schulman
andreas klein
anna greka
arrowhead pharmaceuticals
barry greene
car-t
caron jacobson
cigall kadoch
craig mello
dan ollendorf
dicerna pharamceuticals
dicerna pharmaceuticals
drugs
What
medicines
5
×
drug
rna
cholesterol
deal
dicerna
gene
interference
long
medco
new
pharma
pharmaceuticals
abandoning
acquire
ago
agreed
alnylam
aren’t
baggage
based
billion
brings
car
cash
caught
causing
companies
company
compound
cuts
cutting
data
development
disease
edge
evidence
experiments
eye
fda
Language
unset
Current search:
" national blog main "
×
medicines
×
" rna interference "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”